Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Published byNorma Thornton Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint."— Presentation transcript:

1 Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. C57/BL6 reovirus-vaccinated mice (22) were injected with GL261 cells intracranially on day 1 and treated using combinations of granulocyte-macrophage colony-stimulating factor (GM-CSF) plus intravenous reovirus and/or anti–PD-1 antibody. (A) Kaplan-Meier survival plot, with Mantel-Cox comparison of survival curves: control versus anti–PD-1 (P = ), control versus GM-CSF/reovirus (P = ), control versus GM-CSF/reovirus + anti–PD-1 (P < ), GM-CSF/reovirus versus GM-CSF/reovirus + anti–PD-1 (P < ), and anti–PD-1 versus GM-CSF/reovirus + anti–PD-1 (P < ). (B) Representative brain tumor hematoxylin and eosin–stained sections from PBS-treated and GM-CSF/reovirus-treated mice. Black arrows mark vascular endothelial cells; white arrows mark lymphocytes. Scale bars, 30 μm. (C) Flow cytometry quantification of CD3+ CD4+ IFN-γ+ or CD3+ CD8+ IFN-γ+ TILs from PBS-treated or GM-CSF/reovirus-treated mice. Graph shows the mean ± SD of four samples. Adel Samson et al., Sci Transl Med 2018;10:eaam7577 Published by AAAS

Download ppt "Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint."

Similar presentations

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Dual anti‐Ang‐2 and anti‐VEGF therapy acts synergistic on vascular normalization and macrophage infiltration in experimental GBM Dual anti‐Ang‐2 and anti‐VEGF.

Dual anti‐Ang‐2 and anti‐VEGF therapy acts synergistic on vascular normalization and macrophage infiltration in experimental GBM Dual anti‐Ang‐2 and anti‐VEGF.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.
Intravenous delivery of reovirus to primary and secondary brain tumors

Intravenous delivery of reovirus to primary and secondary brain tumors
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,
Expression of CD36 and psap in a TMA of human ovarian cancer patients

Expression of CD36 and psap in a TMA of human ovarian cancer patients
Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 5 A competent Fc is required for the antitumor immune response.
Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.
Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 4. Specific versus nonspecific NP accumulation.

Similar presentations

Ads by Google